Skip to main content Accessibility help
×
Hostname: page-component-84b7d79bbc-g7rbq Total loading time: 0 Render date: 2024-07-26T00:15:31.088Z Has data issue: false hasContentIssue false

70 - Heparin

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Hep-lock, Hepflush

Generic?

• Yes

Class

• Anticoagulant

Commonly Prescribed for

(FDA approved in bold)

Deep venous thrombosis (DVT)/pulmonary embolism (PE)

Atrial fibrillation with embolization

Prevention of evolving thrombosis in acute ischemic stroke (AIS)

Coagulopathies (acute and chronic)

Prophylaxis against postoperative DVT/PE in at-risk patients

Clotting prevention (i.e., during procedures)

• Prophylaxis of left ventricular thrombi and cerebrovascular accidents post-myocardial infarction (MI)

• Cerebral venous sinus thrombosis (CVST)

• During percutaneous coronary intervention (PCI), to mitigate plaque rupture and reduce thrombosis

• Unstable angina

How the Drug Works

• Inhibits multiple sites in the coagulation system, preventing normal clotting of blood and formation of fibrin clots. Heparin, in combination with antithrombin III, inactivates activated Factor X and prevents the conversion of prothrombin to thrombin

• Larger doses inhibit further coagulation by inactivating thrombin and preventing conversion of fibrinogen to fibrin and inhibiting the activation of fibrin stabilizing factor

How Long Until It Works

• IV bolus: anticoagulant effect is immediate but increases in proportion to dose and duration of use. SC: peak levels occur at 2–4 hours

If It Works

• Monitor for bleeding complications and check activated partial thromboplastin time (aPTT)

If It Doesn't Work

• Patients can still have DVT/PE or IS despite treatment. Check aPTT to determine effectiveness

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Often used with aspirin adjunctively in the setting of acute MI and coronary occlusion

• Usually used in acute setting after cardioembolic IS. Warfarin is usually used for long-term prophylaxis

Tests

• Monitor aPPT to determine effectiveness. Periodically monitor platelet counts and test for occult blood in stool

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Anticoagulation increases bleeding risk, hypersensitivity accounts for most of the other AEs

Notable AEs

• Generalized hypersensitivity (chills, fever, urticaria, rhinitis, headache). Mild thrombocytopenia. Osteoporosis with extended use

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 258 - 261
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Heparin
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.071
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Heparin
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.071
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Heparin
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.071
Available formats
×